What is the aim of this Cochrane Review?
People with blood infections need urgent treatment with antibiotics. Identifying the bacteria causing the infection helps ensure the right antibiotic is given. Rapid susceptibility tests are a technology to do this quickly, and aim to improve care. We sought to evaluate whether their use reduce deaths or shortens the illness.
Rapid susceptibility tests to identify an appropriate antibiotic quickly for people with blood sepsis may make little to no difference to:
· how many people die within 30 days of diagnosis of blood sepsis;
· how long people stay in hospital;
· whether given a suitable antibiotic.
Larger studies will help determine if using rapid susceptibility tests improves these outcomes.
What was studied in this review?
Susceptibility tests are done in a laboratory, and measure whether bacteria can grow when exposed to a variety of antibiotics, to assure that the antibiotics given are active against the organism causing the infection. The standard approach is to culture the blood samples, but this takes up to 36 hours to obtain a result. Rapid tests to identify bacteria causing blood infections, and their susceptibilities to antibiotics, provide results in eight hours or less. These rapid susceptibility tests include:
· tests that look at the direct effect of antibiotics on bacteria (called phenotypic tests); and
· tests that look for particular genes in the bacteria to see if they are susceptible, or resistant, to an antibiotic (called genotypic tests).
What are the main results of this review?
We found six studies that involved 1638 adults with blood infections. All studies took place in specialized medical centres in high-income countries in Europe, the USA, and East Asia.
Compared with standard tests, rapid susceptibility tests may make little to no difference to
· how many people died within 30 days (evidence from six studies in 1638 people);
· how long people stayed in hospital (4 studies in 1165 people); or
· how long it took for people to be given the right antibiotic to treat the infection (5 studies in 1493 people).
Phenotypic rapid susceptibility tests may reduce the time it takes to receive the right antibiotic; but this is uncertain (evidence from 2 studies in 564 people).
Genotypic rapid susceptibility tests may make little or no difference to the time it takes to receive the right antibiotic (evidence from 4 studies in 1074 people).
Our confidence in the results is limited because:
· the numbers of deaths reported in the studies were too low to show an important difference;
· the tests used and the results from the studies varied widely;
· the studies did not include enough participants to enable firm conclusions.
Further research is likely to change these results.
How up to date is this review?
We included evidence published up to 21 October 2020.
The theoretical benefits of rapid susceptibility testing have not been demonstrated to directly improve mortality, time-to-discharge, or time-to-appropriate antibiotic in these randomized studies. Future large prospective studies should be designed to focus on the most clinically meaningful outcomes, and aim to optimize blood culture pathways.
Rapid antimicrobial susceptibility tests are expected to reduce the time to clinically important results of a blood culture. This might enable clinicians to better target therapy to a person's needs, and thereby, improve health outcomes (mortality, length of hospital stay), and reduce unnecessary prescribing of broad-spectrum antibiotics; thereby reducing antimicrobial resistance rates.
To assess the effects of rapid susceptibility testing versus standard susceptibility testing for bloodstream infections (BSIs).
To identify studies with selected outcomes, we searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, LILACS, and two trials registries, between 1987 and October 2020. We used 'bloodstream infection' and 'antimicrobial susceptibility tests' as search terms. We had no language or publication status limitations.
Randomized controlled trials (RCTs) comparing rapid antimicrobial susceptibility testing (with a time-to-result of ≤ 8 hours) versus conventional antimicrobial susceptibility testing in people with a BSI caused by any bacteria, as identified by a positive blood culture.
Two review authors independently screened references, full-text reports of potentially relevant studies, extracted data from the studies, and assessed risk of bias. Any disagreement was discussed and resolved with a third review author. For mortality, a dichotomous outcome, we extracted the number of events in each arm, and presented a risk ratio (RR) with 95% confidence interval (CI) to compare rapid susceptibility testing to conventional methods. We used Review Manager 5.4 to meta-analyse the data. For other outcomes, which are time-to-event outcomes (time-to-discharge from hospital, time-to-first appropriate antibiotic change), we conducted qualitative narrative synthesis, due to heterogeneity of outcome measures.
We included six trials, with 1638 participants. For rapid antimicrobial susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups (RR 1.10, 95% CI 0.82 to 1.46; 6 RCTs, 1638 participants; low-certainty evidence). In subgroup analysis, for rapid genotypic or molecular antimicrobial susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups (RR 1.02, 95% CI 0.69 to 1.49; 4 RCTs, 1074 participants; low-certainty evidence). For phenotypic rapid susceptibility testing compared to conventional methods, there was little or no difference in mortality between groups (RR 1.37, 95% CI 0.80 to 2.35; 2 RCTs, 564 participants; low-certainty evidence).
In qualitative analysis, rapid susceptibility testing may make little or no difference in time-to-discharge (4 RCTs, 1165 participants; low-certainty evidence). In qualitative analysis, rapid genotypic susceptibility testing compared to conventional testing may make little or no difference in time-to-appropriate antibiotic (3 RCTs, 929 participants; low-certainty evidence). In subgroup analysis, rapid phenotypic susceptibility testing compared to conventional testing may improve time-to-appropriate antibiotic (RR -17.29, CI -45.05 to 10.47; 2 RCTs, 564 participants; low-certainty evidence).